

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	Continuation of 09/265,299
Filing Date	March 7, 2001
First Named Inventor	Stephen T. Sonis
Group Art Unit	
Examiner Name	

U.S. PRO 03/07/01
1065800855

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CMM	4,666,897	Golub, et al.		05-19-1987		
	5,190,917	Lezdey, et al.		03-02-1993		
	5,192,780	York, et al.		03-09-1993		
	5,215,965	Lezdey, et al.		06-01-1993		
	5,230,895	Czarnecki, et al.		06-27-1993		
	5,310,545	Eisen		05-10-1993		
	5,385,941	Fawzi, et al.		01-31-1995		
	5,512,055	Domb, et al.		04-30-1996		
	5,578,315	Chien, et al.		11-26-1996		
	5,654,312	Andrulis, Jr., et al.		09-05-1997		
	5,674,708	Cooperman, et al.		10-07-1997		
	5,707,653	Goldberg		01-13-1998		
	5,788,982	Nadoolman, et al.		08-04-1998		
	5,824,297	Iwata, et al.		10-20-1998		
	5,846,525	Maniar, et al.		12-08-1998		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
CMM	JP	7069851	A	Lion Corp.	03-14-1995			
CMM	JP	8268854	A	Sunstar KK	10-15-1996			
CMM	EP	0 355 067	A1	Celltech Ltd.	02-12-1990			
CMM	WO	95/17154	A2	Andrulis Pharmaceutical Corporation	06-29-1995			
CMM	WO	97/09973	A2	The Regents of the University of California	03-20-1997			

Examinee Signature	CMM	Date Considered	2/10/02
--------------------	-----	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/265,299
Sheet	2	of	6
		Attorney Docket Number	MT 100 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AMM		AMIN, et al., "A novel mechanism of action of tetracyclines: effects on nitric oxide synthases," <i>Proc Natl Acad Sci U S A</i> . 93(24):14014-9 (1996).	
		AMON, et al., "CGP 41251, a novel protein kinase inhibitor with in vitro selectivity for protein kinase C, strongly inhibits immunological activation of human skin mast cells and human basophils," <i>Pharmacology</i> . 47(3):200-8 (1993).	
		ARMITAGE, et al., "Microscopic evaluation of clinical measurements of connective tissue attachment levels," <i>Journal of Clinical Periodontology</i> 4:173-190 (1977).	
		BACH, et al., "Experiments on the mode of action of piritropine (U-60,257), an inhibitor of leukotriene formation in cloned mouse mast cells and in rat basophil leukemia cells," <i>Biochem Pharmacol</i> . 36(9):1461-6 (1987).	
		BADGER, et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," <i>J Pharmacol Exp Ther</i> . 279(3):1453-61 (1996).	
		BALLA, et al., "Tissue responses to furcation perforations repaired with various dental materials," <i>Journal of Dental Research</i> 68:1144 (1989).	
AMM		BAUDITZ, et al., "Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease," <i>Gut</i> . 40(4):470-4 (1997).	
AMM		BONDI, et al., "Local antimicrobial therapy of oral mucositis in Paediatric patients undergoing bone marrow transplant," <i>Oral Oncology</i> 33:322-326 (1997).	
AMM		CAUGHEY, et al., "Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases," <i>J Pharmacol Exp Ther</i> . 264(2):676-82 (1993).	
AMM		CZARNETZKI, et al., "Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema," <i>Dermatology</i> 187:112-114 (1993).	

Examiner's Signature

AMM

Date Considered

2/10/02 | 8/4/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/265,299
Sheet	3	of	6
		Attorney Docket Number	MT 100 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CRM		DE PAULIS, et al., "FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI + cells," <i>J Immunol.</i> 146(7):2374-81 (1991).	
		FEWTRELL & GOMPERTS, "Quercetin: a novel inhibitor of Ca ²⁺ influx and exocytosis in rat peritoneal mast cells," <i>Biochimica et Biophysica Acta</i> 469:52-60 (1977).	
		FIRARLI, et al. "Antioxidative activities of some chemotherapeutics. A possible mechanism in reducing gingival inflammation," <i>J Clin Periodontol.</i> 21(10):680-3 (1994).	
		GILBERTSON-BEADLING, et al., "The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism," <i>Cancer Chemother Pharmacol.</i> 36(5):418-24 (1995).	
CRM		GREENWALD, et al., "Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage," <i>J Rheumatol.</i> 19(6):927-38 (1992).	
CRM		HALLAHAN, et al., "Ketoconazole attenuates radiation-induction of tumor necrosis factor," <i>Int J Radiat Oncol Biol Phys.</i> 29(4):777-80 (1994).	
		HANAZAWA, et al., "Expression of Monocyte Chemoattractant Protein 1 (MCP-1) in Adult Periodontal Disease: Increased Monocyte Chemoattractant Activity in Crevicular Fluids and Induction of MCP-1 Expression in Gingival Tissues," <i>Infection and Immunity</i> 61:5219-5224 (1993).	
		HANAZAWA, et al., "Functional Role of Interleukin 1 in Periodontal Disease: Induction of Interleukin 1 Production by <i>Bacteroides gingivalis</i> Lipopolysaccharide in Peritoneal Macrophages from C3H/HeN and C3H/HeH Mice," <i>Infection and Immunity</i> 50:262-270 (1985).	
		HANEMAAIJER, et al., "Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells," <i>Adv Dent Res.</i> 12(2):114-8 (1998).	
		HATTORI, et al., "A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice," <i>Blood.</i> 90(2):542-8 (1997).	

Examiner's Signature	CRM	Date Considered	2/10/02 8/4/03
----------------------	-----	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-98)
Approved for use through 10/31/98. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 09/265,299
Sheet	4	of	6	Filing Date	March 7, 2001
				First Named Inventor	Stephen T. Sonis
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	MT 100 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CM	HU, et al., "I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis," <i>J Biol Chem.</i> 272(28):17255-7 (1997).		
	JANDINSKI, et al., "Interleukin- Beta in Crevicular Fluids During Periodontal Health and Disease," <i>Journal of Dental Research Abstracts</i> 68:1233 (1989).		
	JEFFCOAT, et al., "Treatment of periodontal disease in beagles with Iodozamide ethyl, an inhibitor of mast cell release," <i>Journal of Periodontal Research</i> 20:532-541 (1985).		
	JOHNSON, et al., "The characterization of Iodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma," <i>Agents Actions.</i> 18(3-4):301-5 (1986).		
	KAMAGATA, et al., "Cytokine Production in Human Inflamed Gingival Tissue," <i>Journal of Dental Research Abstracts</i> 68:525 (1989).		
	MCGEEHAN, et al., "Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor," <i>Nature.</i> 370(6490):558-61 (1994).		
	MORIMOTO, et al., "KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor- production," <i>Life Sciences</i> 61:795-803 (1997).		
	MÜLLBERG, et al., "A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor," <i>J Immunol.</i> 155(11):5198-205 (1995).		
✓	MURAKAMI, et al., "Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes," <i>Crit Care Med.</i> 24(6):1047-53 (1996).		
CM	Physicians Desk Reference, 51st Edition, p. 2232, 1997.		

Examiner's Signature *CM* Date Considered 2/10/02 8/4/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/265,299
Sheet	5	of	6
		Attorney Docket Number	MT 100 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CRM	PILLSBURY, et al., "Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers," <i>Arch Otolaryngol Head Neck Surg.</i> 112(5):552-3 (1986).		
CRM	PIRIE-SHEPHERD, et al., "Differential inhibition of rat mast cell proteinase I and II by members of the -1- proteinase inhibitor family of serine proteinase inhibitors," <i>The Journal of Biological Chemistry</i> 266:17314-17319 (1991).		
J	RANNEY & MONTGOMERY, "Vascular Leakage Resulting from Topical Application of Endotoxin to the Gingiva of the Beagle Dog," <i>Archs oral Biol.</i> 18:963-970 (1973).		
CRM	RENGGLI & REGOLATI, "Intracrevicular sampling of leukocytes using plastic strips," <i>Helv. Odont. Acta</i> 16:93-99 (1972).		
CRM	ROTHWELL & SPEKTOR, "Palliation of radiation-related mucositis," <i>Spec Care Dentist.</i> 10(1):21-5 (1990).		
CRM	SCHENK, et al., "Controlled local delivery of tetracycline HCl in the treatment of periimplant mucosal hyperplasia and mucositis. A controlled case series," <i>Clin Oral Implants Res.</i> 8(5):427-33 (1997).		
CRM	SIEGEL, et al., "The measurement of gingival fluid," <i>J. Periodontol.</i> 43:682-684 (1972).		
	SINCHOLLE, et al., "Anti-inflammatory activity of a dual inhibitor of cyclooxygenase and lipoxygenase pathways, CBS-1108 (2-acetylthiophene-2-thiazolylhydrazone)," <i>Arzneimittelforschung.</i> 35(8):1260-3 (1985).		
	SINGH, et al., "Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents," <i>J Immunol.</i> 157(10):4412-20 (1996).		
V	SONIS, "Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity," <i>Oral Oncol.</i> 34(1):39-43 (1998).		

Examiner's Signature	CRM	Date Considered	2/10/02 8/4/03
----------------------	-----	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/265,299
Filing Date	March 7, 2001		
First Named Inventor	Stephen T. Sonis		
Group Art Unit			
Examiner Name			
Sheet	6	of	6
			Attorney Docket Number
			MT 100 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>UJM</i>		TILG, et al., "Immune response modulation by pentoxyfylline in vitro," <i>Transplantation</i> 56:196-201 (1993).	
<i>UJM</i>		TRIPPLETT, et al., "SK&F 86002, a dual cytokine and eicosanoid inhibitor, attenuates endotoxin-induced	
<i>UJM</i>		cardiopulmonary dysfunction in the pig," <i>Shock</i> , 6(5):357-64 (1996).	
<i>UJM</i>		VERDI, et al., "Cancer Therapy and Oral Mucositis," <i>Drug Safety</i> 9:185-195 (1993).	
		WALSH, et al., "Relationship between mast cell degranulation and inflammation in the oral cavity," <i>J Oral Pathol Med</i> ,	
		24(6):266-72 (1995).	

Examiner's Signature	CJM	Date Considered	2/10/02	8/4/03
----------------------	-----	-----------------	---------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.